Pasta dental medicada con atorvastatina inhibe de forma significativa la proliferación de Células T CD4+: Un estudio piloto in vitro

Simple item page
dc.coverageDOI: 10.4067/S0717-95022017000200002
dc.creatorRosenberg, David
dc.creatorKernitsky, Jeremy R.
dc.creatorAndrade, Catherine X.
dc.creatorRamírez, Valeria
dc.creatorViolant, Deborah
dc.creatorNart, José
dc.date2017
dc.date.accessioned2025-11-18T19:53:31Z
dc.date.available2025-11-18T19:53:31Z
dc.description<p>Reports indicate that statins (cholesterol-lowering drugs), in addition to lowering cholesterol, have an immunomodulatory effect. This effect may be beneficial for the treatment of several diseases, including periodontal disease. The aim of the present study was to evaluate the immunomodulatory effect of an atorvastatin-medicated dentifrice on CD4+ T cell proliferation. CD4+ T cell proliferation assays and peripheral blood mononuclear cell (PBMC) viability assays were conducted on PBMCs from healthy donors cultured under the following conditions: control, atorvastatin solution, atorvastatin-medicated dentifrice, and dentifrice without atorvastatin at concentrations of 1, 5, 10, 50 and 100 µM. A Generalized Equation Estimation (GEE) model was used to analyze concentration versus proliferation and concentration versus percentage of dead cells within each group evaluated. Atorvastatin-medicated dentifrice (p-value &lt;0.0001) and atorvastatin solution (p-value &lt;0.0001) significantly inhibited CD4+ T cell proliferation in a dosedependent manner compared with the dentifrice without atorvastatin and control conditions. Only the relationship between atorvastatin solution and percentage of dead cells was significant compared to the other conditions (p-value 0.019). The results revealed that atorvastatinmedicated dentifrice at concentrations of 1 to 100 µM had immunomodulatory effects, inhibiting CD4+ T cell proliferation without affecting PBMC viability. The other components of the dentifrice did not affect CD4+ T cell proliferation or cell viability, indicating its utility as a vehicle to achieve the desired effects of atorvastatin in periodontal tissue. Controlled clinical trials are still needed to evaluate the clinical effects of an atorvastatin-medicated dentifrice on the periodontium.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/281221d8-3737-4b28-8ff9-e26b584cf51d
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/58297
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.35 (2017) nr.2 p.394-402
dc.subjectAtorvastatin calcium
dc.subjectDentifrices
dc.subjectFlow cytometry
dc.subjectT cells
dc.titlePasta dental medicada con atorvastatina inhibe de forma significativa la proliferación de Células T CD4+: Un estudio piloto in vitrospa
dc.titleAtorvastatin-medicated dentifrice significantly inhibits CD4+ T cell proliferation: In vitro pilot studyeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE